SurvivorNet on MSN

New approval means more bladder cancer patients can access powerful immunotherapy combination: What to know about Keytruda + Padcev

A new treatment combination - Keytruda plus Padcev - is now approved for use before and after bladder‑removal surgery, ...
WebMD

Keytruda and Padcev: FDA Approves New Combination Therapy for Aggressive Bladder Cancer

What Is Keytruda/Padcev Combination Therapy, and Why Does It Matter? The FDA has approved a new combination therapy that uses two different types of anticancer medicines for treating adults with ...
WebMD

Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph) - Uses, Side Effects, and More

Overview: Keytruda Qlex is a medicine that is used to treat many types of cancer. This medicine is given to you as an injection under your skin by a health care provider. This medicine can cause side ...
FiercePharma

Merck's Keytruda hits overall survival goal in early lung cancer as FDA decision nears

What doctors described as a “messy” treatment landscape in early-stage non-small cell lung cancer (NSCLC) could get clearer thanks to a first-in-class overall survival win from Merck & Co.’s Keytruda.
Cure Today

Approval of Pre- and Post-Operative Keytruda a ‘Big Step Forward’ for Lung Cancer

An expert explains the recent movement towards the use of immunotherapy for patients with resectable NSCLC. The recent approval by the Food and Drug Administration (FDA) of Keytruda (pembrolizumab) ...
Monthly Prescribing Reference

Keytruda Qlex, an SC Formulation of Pembrolizumab, Gets FDA Approval

Keytruda Qlex must be administered by a health care provider. The Food and Drug Administration (FDA) has approved Keytruda Qlex ™ (pembrolizumab and berahyaluronidase alfa-pmph) for patients aged 12 ...
FiercePharma

Merck, eyes on Roche’s immunotherapy first, returns perplexing Keytruda post-surgery lung cancer data

Merck & Co.’s Keytruda reigns over the immuno-oncology market for metastatic lung cancer. But in controlling earlier-stage disease, the anti-PD-1 therapy has posted some perplexing results. When used ...
Cure Today

Keytruda Combo Improves Progression, Survival in Recurrent Ovarian Cancer

Keytruda with paclitaxel, with or without Avastin, improved PFS and OS in PRROC patients, irrespective of PD-L1 status. The trial showed significant benefits in both CPS ≥1 and intention-to-treat ...
Reuters

Focus: Merck could keep its patent edge by shifting Keytruda cancer drug to a simple shot

Dec 2 (Reuters) - U.S. drugmaker Merck & Co (MRK.N), opens new tab hopes to patent a new formulation of its $20 billion cancer immunotherapy Keytruda that can be injected under the skin, allowing it ...
STAT

Merck rolls out some showstoppers at a major cancer conference. Its future may depend on them

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. BERLIN — At a prime-time session on ...
The Chosun Ilbo on MSN

48 trillion won Keytruda biosimilar race heats up

Samsung Bioepis, a company developing biosimilars and new drugs, announced the interim results of its phase 1 and phase 3 ...